KRAS and colorectal cancer: Retrospective analysis of the previous blood samples revealed detectable levels of KRAS mutant ctDNA prior to immunotherapy (3 c/mL), suggesting that colorectal cancer may have already been present at the time of stage IV melanoma diagnosis.